RCOR2 and neoplasm: Given that tumor-related epigenetic dysregulation and abnormal cell proliferation likely exert stronger effects on RCOR2 expression than physiological hormonal changes, and considering the paired tissue design from the same patients, potential confounding from menstrual cycle phases is minimal.